Ireland (IE)

Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis (2022) Li Bassi G, Gibbons K, Suen JY, Dalton HJ, White N, Corley A, Shrapnel S, et al. Journal article "Flexures and bends of the large intestine: Current terminology and a suggestion to simplify it" (2022) Wozniak S, Quondamatteo F, Paulsen F Journal article Towards a harmonized European surveillance for dietary and physical activity indicators in young and adult populations (2022) Hebestreit A, Do S, Wolters M, Mensink GB, Garnica-Rosas L, Abu-Omar K, Messing S, et al. Journal article The Physical Activity Environment Policy Index for monitoring government policies and actions to improve physical activity (2022) Woods CB, Kelly L, Volf K, Gelius P, Messing S, Forberger S, Lakerveld J, et al. Journal article The impact of mass-media campaigns on physical activity: a review of reviews through a policy lens (2022) Den Braver NR, Bengoechea EG, Messing S, Kelly L, Schoonmade LJ, Volf K, Zukowska J, et al. Journal article Cardiovascular Risk Reduction After Renal Denervation According to Time in Therapeutic Systolic Blood Pressure Range (2022) Mahfoud F, Mancia G, Schmieder R, Ruilope L, Narkiewicz K, Schlaich M, Williams B, et al. Journal article CAD-RADS™ 2.0 - 2022 Coronary Artery Disease - Reporting and Data System.: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT), the American College of Cardiology (ACC), the American College of Radiology (ACR) and the North America Society of Cardiovascular Imaging (NASCI) (2022) Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, Budoff M, et al. Journal article, Original article CAD-RADS(TM) 2.0-2022 Coronary Artery Disease-Reporting and Data System (2022) Cury RC, Leipsic J, Abbara S, Achenbach S, Berman D, Bittencourt M, Budoff M, et al. Journal article New Way to “SCORE” Risk: Updates on the ESC Scoring System and Incorporation into ESC Cardiovascular Prevention Guidelines (2022) Graham IM, Di Angelantonio E, Huculeci R Journal article, Review article Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients (pts) with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant chemotherapy (NACT) (2022) Marme F, Hanusch C, Furlanetto J, Morris P, Link T, Denkert C, Fasching P, et al. Conference contribution